Format

Send to

Choose Destination
Eur J Med Chem. 2017 Aug 18;136:420-427. doi: 10.1016/j.ejmech.2017.05.021. Epub 2017 May 10.

Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.

Author information

1
Chemistry Platform, Institut Pasteur Korea, 16 Daewangpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea; College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
2
Chemistry Platform, Institut Pasteur Korea, 16 Daewangpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.
3
College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
4
Qurient Co. Ltd., 242 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea.
5
College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea. Electronic address: pennkim@snu.ac.kr.
6
Chemistry Platform, Institut Pasteur Korea, 16 Daewangpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea. Electronic address: silanediol@gmail.com.

Abstract

A set of fused ring analogues of a new antitubercular agent, Q203, was designed and synthesized. To reduce the lipophilicity of Q203 caused by linearly extended side chains, shorter and heteroatoms containing fused rings were introduced into the side chain region. Antitubercular activity was tested against H37Rv-GFP replicating in liquid broth culture medium (extracellular) and within macrophages (intracellular). Many analogues showed potent extracellular activities as well as intracellular activities without cytotoxicity. Among them, compounds 18-21 displayed significant antitubercular activities with favorable metabolic stabilities. Representative compound 21 exhibited excellent in vivo pharmacokinetic values at high drug exposure levels in the plasma, which makes this compound promising candidate for a new antitubercular drug.

KEYWORDS:

Imidazo[1,2-a]pyridine-3-carboxamide (IPA); Pharmacokinetics (PK); Q203; Structure-activity relationship (SAR); Tuberculosis

PMID:
28527405
DOI:
10.1016/j.ejmech.2017.05.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center